Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.745
-0.065 (-3.59%)
Aug 28, 2026, 12:04 PM EDT - Market open
Annovis Bio Employees
Annovis Bio had 7 employees as of December 31, 2025. The number of employees decreased by 8 or -53.33% compared to the previous year.
Employees
7
Change (1Y)
-8
Growth (1Y)
-53.33%
Revenue / Employee
n/a
Profits / Employee
-$7,074,895
Market Cap
74.35M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | -8 | -53.33% | 7 | 0 |
| Dec 31, 2024 | 15 | -1 | -6.25% | 8 | 7 |
| Dec 31, 2023 | 16 | 11 | 220.00% | 6 | 10 |
| Dec 31, 2022 | 5 | 2 | 66.67% | 5 | 0 |
| Dec 31, 2021 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Elicio Therapeutics | 33 |
| Cardiff Oncology | 31 |
| NeurAxis | 24 |
| Gain Therapeutics | 21 |
| LeonaBio | 19 |
| Cingulate | 14 |
| Alterity Therapeutics | 9 |
| Dogwood Therapeutics | 8 |
ANVS News
- 17 hours ago - Annovis Bio price target lowered to $7 from $8 at Roth Capital - TheFly
- 3 days ago - Annovis to Host Corporate Update Webinar on September 2, 2026 - GlobeNewsWire
- 3 days ago - Annovis Bio Proxy statement: Proxy filing - Filings
- 14 days ago - Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - GlobeNewsWire
- 14 days ago - Annovis Bio Earnings release: Q2 2026 - Filings
- 14 days ago - Annovis Bio Quarterly report: Q2 2026 - Filings
- 25 days ago - Annovis Bio Slides: Investor presentation - Filings
- 7 weeks ago - Annovis Bio initiated with a Buy at Roth Capital - TheFly